文献速递眼底病与葡萄膜炎

厚脉络膜型与非厚脉络膜型息肉状脉络膜血管病变的差异及其对抗血管内皮生长因子治疗的反应

DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
PubMed 文献 · Retina · 2020-01-01

研究连续纳入62例未治疗息肉状脉络膜血管病变患者(66眼),发现中心凹下脉络膜厚度是抗VEGF疗效的唯一显著相关因素,最佳截断值为267.5微米。厚脉络膜组较非厚脉络膜组年龄更轻、AMD样特征更少、CSCR样特征更多,且3个月抗VEGF治疗反应更差。

要点

  • 中心凹下脉络膜厚度是PCV抗VEGF治疗效果的唯显著相关因素,最佳截断值267.5微米。
  • 厚脉络膜组较非厚脉络膜组年龄更轻(64.1±9.6岁 vs 72.0±8.2岁,P=0.004)。
  • 厚脉络膜组3个月抗VEGF治疗反应率27.8% vs 非厚脉络膜组83.3%(P<0.0001)。

核心结论

  • PCV患者可再分为厚脉络膜型和非厚脉络膜型,厚脉络膜型年龄更轻、AMD样特征更少、CSCR样特征更多,且对抗VEGF治疗反应更差。

研究设计与样本

  • 研究纳入62例连续、未治疗过的PCV患者共66眼,分析包括中心凹下脉络膜厚度在内的临床特征与3个月抗VEGF治疗反应的相关性。
  • 以约登指数确定SFCT最佳截断值,将患者分为厚脉络膜组和非厚脉络膜组,比较两组人口学特征、临床特征及抗VEGF治疗反应。

主要发现

  • 中心凹下脉络膜厚度是治疗效果的唯显著因素,最佳截断值为267.5微米。
  • 厚脉络膜组年龄64.1±9.6岁 vs 非厚脉络膜组72.0±8.2岁(P=0.004),厚脉络膜组更年轻。
  • 厚脉络膜组AMD样特征50.0% vs 非厚脉络膜组81.3%(P=0.027),厚脉络膜组更少。
  • 厚脉络膜组典型RPE斑驳61.1% vs 非厚脉络膜组16.7%(P=0.0014),脉络膜血管高渗透性88.9% vs 37.5%(P=0.0002),厚脉络膜组CSCR样特征更多。
  • 厚脉络膜组3个月抗VEGF治疗反应27.8% vs 非厚脉络膜组83.3%(P<0.0001),厚脉络膜组反应更差。

关键数值与推荐

  • SFCT最佳截断值为267.5微米,用于区分厚脉络膜组与非厚脉络膜组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent investigations have found a biphasic pattern of choroidal thickness within polypoidal choroidal vasculopathy (PCV) patients. This study aims to investigate the relationship between choroidal thickness and the clinical features of PCV eyes. METHOD: We investigated the correlation between various clinical features including subfoveal choroidal thickness (SFCT) and the response to 3-monthly anti-vascular endothelial growth factor (VEGF) treatments in 62 consecutive, treatment-naive PCV patients (66 eyes). After finding out SFCT as the only factor that was correlated with anti-VEGF treatment, we then set up to determine a best cutoff line for SFCT that could be used as a parameter to differentiate PCV patients into pachychoroid and nonpachychoroid groups using the Youden index for best combined specificity and sensitivity. We then compared the demographic features, clinical characteristics, and the response to anti-VEGF between both groups, to determine whether there is a difference between these two groups. RESULTS: Subfoveal choroidal thickness was the only significant factor for the treatment effect. The SFCT of 267.5 µm is the best cutoff line. The pachychoroid group showed significant younger ages (64.1 ± 9.6 vs. 72.0 ± 8.2, P = 0.004), fewer age-related macular degeneration-like features (50.0 vs. 81.3%, P = 0.027), more central serous chorioretinopathy-like features (typical retinal pigment epithelial mottling [61.1 vs. 16.7%, P = 0.0014] and choroidal vascular hyperpermeability [88.9 vs. 37.5%, P = 0.0002]), and less response to 3-monthly anti-VEGF treatments (27.8 vs. 83.3%, P < 0.0001) as compared to the nonpachychoroid group. CONCLUSION: Polypoidal choroidal vasculopathy patients could be subclassified into pachychoroid and nonpachychoroid groups. The pachychoroid subtype of PCV has significantly younger ages, fewer age-related macular degeneration-like features, more central serous chorioretinopathy-like features, and less response to anti-VEGF treatment.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Chang YC, Cheng CK. DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2020. PMID: 31181038. doi:10.1097/IAE.0000000000002583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。